Louis Lerebours, MD
Addiction Medicine · Nashville, TNNPI 1851821649
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Indivior Inc. at 38.2% of the total. 2025 is the largest year on record at $1,357, more than ten times the $104 reported in 2019.
Across 58 payments — averaging $30.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$680
- Braeburn Inc.$370
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$271
- Alkermes, Inc.$178
- AbbVie$107
- E.r. Squibb & Sons, L.L.C.$104
- plus $68 from 4 others
What the payments were for
- Food & beverage$1,778100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 25 | $680 |
| Braeburn Inc. | 14 | $370 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $271 |
| Alkermes, Inc. | 6 | $178 |
| AbbVie | 1 | $107 |
| E.r. Squibb & Sons, L.L.C. | 1 | $104 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Pfizer | 1 | $14 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,778 in reported general payments places this provider in the 80th percentile of 76 addiction medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 298 | $37,307 |
| Buprenorphine Hcl | 28 | $848 |
| Gabapentin | 55 | $678 |
| Quetiapine Fumarate | 16 | $503 |
| Clonazepam | 71 | $240 |
| Hydroxyzine Hcl | 11 | $180 |
| Alprazolam | 17 | $46 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Nashville
- Marie-Louise MengNashville$19K
- Winston GrinerNashville$4K
- Richard SoperNashville$2K
- Susan LimbaughNashville$1K
- Roger JonesNashville$732
- Harold EmbrackNashville$446
- Paul RaganNashville$305
- Michael MillerNashville$262
- Eno EyoNashville$205
- David WeinsteinNashville$165
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.